Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Clemmons

Showing results (21-30 of 113) with videos related to

Pageof 12
Sort By:
The Journal of Clinical Endocrinology and Metabolism|September 6, 2002
IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanismsThomas O'Connell, David R Clemmons
European Journal of Endocrinology|June 25, 2024
IGF-I assay methods and biologic variability: evaluation of acromegaly treatment responseDavid R Clemmons, Martin Bidlingmaier
Molecular Endocrinology (Baltimore, Md.)|April 6, 2010
AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylationJunyu Ning, David R Clemmons
Frontiers in Endocrinology|November 29, 2023
Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegalyDavid R Clemmons, Martin Bidlingmaier
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|November 9, 2002
Growth hormone receptor antagonist improves insulin resistance in acromegalyD Roderick Rose, David R Clemmons
Endocrinology|April 17, 2003
Minireview: Integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signalingDavid R Clemmons, Laura A Maile
Circulation Research|October 18, 2003
Integrin-associated protein binding domain of thrombospondin-1 enhances insulin-like growth factor-I receptor signaling in vascular smooth muscle cellsLaura A Maile, David R Clemmons
Endocrinology|October 26, 2002
The alphaVbeta3 integrin regulates insulin-like growth factor I (IGF-I) receptor phosphorylation by altering the rate of recruitment of the Src-homology 2-containing phosphotyrosine phosphatase-2 to the activated IGF-I receptorLaura A Maile, David R Clemmons
The Journal of Biological Chemistry|January 10, 2002
Regulation of insulin-like growth factor I receptor dephosphorylation by SHPS-1 and the tyrosine phosphatase SHP-2Laura A Maile, David R Clemmons
Molecular Endocrinology (Baltimore, Md.)|July 9, 2008
p66shc negatively regulates insulin-like growth factor I signal transduction via inhibition of p52shc binding to Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 leading to impaired growth factor receptor-bound protein-2 membrane recruitmentGang Xi, Xinchun Shen, David R Clemmons
Pageof 12

Showing results (21-30 of 113) with videos related to

Sort By:
Pageof 12
The Journal of Clinical Endocrinology and Metabolism|September 6, 2002
IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanismsThomas O'Connell, David R Clemmons
European Journal of Endocrinology|June 25, 2024
IGF-I assay methods and biologic variability: evaluation of acromegaly treatment responseDavid R Clemmons, Martin Bidlingmaier
Molecular Endocrinology (Baltimore, Md.)|April 6, 2010
AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylationJunyu Ning, David R Clemmons
Frontiers in Endocrinology|November 29, 2023
Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegalyDavid R Clemmons, Martin Bidlingmaier
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|November 9, 2002
Growth hormone receptor antagonist improves insulin resistance in acromegalyD Roderick Rose, David R Clemmons
Endocrinology|April 17, 2003
Minireview: Integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signalingDavid R Clemmons, Laura A Maile
Circulation Research|October 18, 2003
Integrin-associated protein binding domain of thrombospondin-1 enhances insulin-like growth factor-I receptor signaling in vascular smooth muscle cellsLaura A Maile, David R Clemmons
Endocrinology|October 26, 2002
The alphaVbeta3 integrin regulates insulin-like growth factor I (IGF-I) receptor phosphorylation by altering the rate of recruitment of the Src-homology 2-containing phosphotyrosine phosphatase-2 to the activated IGF-I receptorLaura A Maile, David R Clemmons
The Journal of Biological Chemistry|January 10, 2002
Regulation of insulin-like growth factor I receptor dephosphorylation by SHPS-1 and the tyrosine phosphatase SHP-2Laura A Maile, David R Clemmons
Molecular Endocrinology (Baltimore, Md.)|July 9, 2008
p66shc negatively regulates insulin-like growth factor I signal transduction via inhibition of p52shc binding to Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 leading to impaired growth factor receptor-bound protein-2 membrane recruitmentGang Xi, Xinchun Shen, David R Clemmons
Pageof 12